Related Experiment Video

Updated: Mar 23, 2026

In Vivo Inhibition of MicroRNA to Decrease Tumor Growth in Mice
07:02

In Vivo Inhibition of MicroRNA to Decrease Tumor Growth in Mice

Published on: August 23, 2019

7.9K

Aurora kinase A induces papillary thyroid cancer lymph node metastasis by promoting cofilin-1 activity

Yusufu Maimaiti1, Tan Jie1, Zhou Jing1

  • 1Department of Breast and Thyroid Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.

Biochemical and Biophysical Research Communications
|March 23, 2016
PubMed

Insights

Aurora-A (Aur-A) and Cofilin-1 (CFL-1) are overexpressed in papillary thyroid cancer, promoting lymph node metastasis. Targeting both Aur-A and CFL-1 may offer a new therapeutic strategy for thyroid cancer treatment.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cell Biology

Background:

  • Aurora-A (Aur-A) is a serine/threonine kinase crucial for cell division and possesses oncogenic properties.
  • Papillary thyroid cancer (PTC) metastasis, driven by cell migration and invasion, is a major cause of mortality.
  • The role of Aur-A in PTC and its association with metastasis were previously unclear.

Purpose of the Study:

  • To investigate the correlation between Aur-A and Cofilin-1 (CFL-1) in PTC with lymph node metastasis.
  • To determine the functional role of Aur-A in thyroid cancer cell migration and metastasis.
  • To explore the potential of Aur-A and CFL-1 as therapeutic targets for PTC.

Main Methods:

  • Tissue microarray analysis of thyroid cancer tissues to assess Aur-A and CFL-1 expression.
  • In vitro assays to evaluate the effect of Aur-A inhibition on thyroid cancer cell migration.
  • In vivo studies using nude mice to assess the impact of Aur-A inhibition on lymph node metastasis.
  • Western blot analysis to examine CFL-1 phosphorylation status in response to Aur-A modulation.

Main Results:

  • Simultaneous overexpression of Aur-A and CFL-1 was significantly correlated with lymph node metastasis in PTC.
  • Inhibition of Aur-A reduced thyroid cancer cell migration in vitro and decreased lymph node metastasis in vivo.
  • Aur-A was found to increase the active, non-phosphorylated form of CFL-1, thereby enhancing cell migration and metastasis.

Conclusions:

  • The combined expression of Aur-A and CFL-1 serves as a potential molecular predictor for lymph node metastasis in thyroid cancer.
  • Targeting Aur-A and CFL-1 concurrently presents a promising therapeutic strategy for improving outcomes in thyroid cancer patients.
  • This study elucidates a novel mechanism by which Aur-A promotes thyroid cancer metastasis via CFL-1 activation.
Keywords:
Aurora kinaseCell motilityCofilin-1MetastasisPapillary thyroid cancer

More Related Videos

Real-Time Monitoring of Aurora kinase A Activation using Conformational FRET Biosensors in Live Cells06:29

Real-Time Monitoring of Aurora kinase A Activation using Conformational FRET Biosensors in Live Cells

Published on: July 30, 2020

3.6K
Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants07:38

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

901

Related Concept Videos

PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
6.2K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
5.0K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

1.6K
Anaphase Promoting Complex00:50

Anaphase Promoting Complex

The stepwise destruction of specific proteins is necessary for the progression and completion of the cell cycle. Such proteins are ubiquitinated by ubiquitin ligases and then subsequently destroyed by the proteasome. The SCF (Skp1/Cullin/F-box) and the anaphase-promoting complex (APC) are two important ubiquitin ligases involved in cell cycle progression. While SCF is active throughout the cell cycle, APC gets activated during metaphase to anaphase transition. Cdc20 or Cdh1 binds to APC and...
3.5K
MAPK Signaling Cascades01:07

MAPK Signaling Cascades

Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
9.1K
M-Cdk Drives Transition Into Mitosis02:15

M-Cdk Drives Transition Into Mitosis

Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
6.8K